Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

FREEDOM-C(2) trial will be announced in September 2011 and that full data from the trial will be presented at an upcoming medical meeting and will also be available in peer-reviewed journal articles.  These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  These risks and uncertainties include, among others, the failure of oral treprostinil to receive regulatory approval at all, or on the schedule expected; the possible inaccuracies of our analysis with respect to the FREEDOM-M preliminary trial results and market opportunity; and our or our suppliers’ inability to manufacture oral treprostinil in accordance with all applicable regulatory requirements and in sufficient quantity to support patient demand.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.  We are providing this information as of June 6, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

REMODULIN and TYVASO are registered trademarks of United Therapeutics Corporation.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 AmerisourceBergen’s ... Canadian specialty market, is now providing U.S. manufacturers ... new 160,000-square-foot distribution center coupled with its fully-licensed ... healthcare industry has historically been difficult for smaller ... government regulation complexities. As a result of these ...
(Date:9/23/2014)... 23, 2014 The print component of ... Metro, with a circulation of approximately 327,720 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with Michael Landsberg, host of TSN’s Off ...
(Date:9/23/2014)... WASHINGTON, Sept. 23, 2014 Antibiotics revolutionized health ... bacteria that once killed thousands of people. But ... strains of antibiotic-resistant bacteria are popping up more ... the current shortage of new antibiotics and discusses ... answers the question: Why should you finish your ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 On September ... by Keith Simmons for an episode. Simmons is the founder ... Deierlein believed the audience would like to know. At the ... get the idea to start this magazine?” Simmons replied by ... advertising sales person. In 2005, I quit that and decided ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... scientists have been chosen from a highly competitive field ... Merck Sharp & Dohme and Advance to boost the ... Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr ... have been selected as joint winners of the 2008 ...
... important international relationships is top of the agenda ... Dr Raisa Monteiro, when she meets with leading ... One of two Australian life scientists chosen from ... prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro ...
... anemia in expectant mothers and spinal birth defects in newborns, the ... has now been shown to blunt the damaging effects of heart ... In a new study, an international team of heart experts at ... daily of folate, also known as folic acid or vitamin B9, ...
... Solution for ... Employers, ... believe the future of managing health care costs lies in,helping their ... Seventh Annual Tri-State Area Employee,Benefit Survey., Cowden Associates, the region,s ...
... US$1.75 million of new available funds -, ... Inc. (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, ... under the agreement to repay US$1.75 million of ... Laurus Master Funds),in common shares., The conversion ...
... ROLLA, Mo., March 27 While today,s shaky economy ... has been an,exception. In fact, there is currently a ... positions. Furthermore, according to the latest,projections from the U.S. ... replacement nurses will be needed by 2014 -- and ...
Cached Medicine News:Health News:Rising Australian biotech stars set to connect on the world stage 2Health News:DendriMed scientist seeks to fast-track success 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 3Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 4Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 2Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 3Health News:Bioniche Converts a Portion of its Debt to Equity 2Health News:NurseAuction.com Aims to Alleviate Nurse Shortage with Online Nurse Bidding 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: